Blood Cancer Discovery

Reconstructing Complex Cancer Evolutionary Histories from Multiple Bulk DNA Samples Using Pairtree
Quaid Morris et al.
Blood Cancer Discovery May 2022

Cancer Discovery

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
Ignacio Melero et al.
Cancer Discov May 2022

Cancer Epidemiology, Biomarkers & Prevention

Neighborhood Obesogenic Environment and Risk of Prostate Cancer: The Multiethnic Cohort
Iona Cheng et al.
Cancer Epidemiol Bio Prev May 2022

Cancer Immunology Research

Phosphoantigen-Stimulated γδ T Cells Suppress Natural Killer–Cell Responses to Missing-Self
Zakia Djaoud et al.
Cancer Immunol Res May 2022

Cancer Prevention Research

Implementing Strategies at the Workplace Level to Increase Colorectal Cancer Screening Uptake in Argentina: A Controlled Interrupted Time-series Study
Lucas Angel González et al.
Cancer Prev Res May 2022

Cancer Research

Secretion of IL1 by Dedifferentiated Melanoma Cells Inhibits JAK1-STAT3–Driven Actomyosin Contractility of Lymph Node Fibroblastic Reticular Cells
Virginie Prod'homme et al.
Cancer Res May 2022

Liver Colonization by Colorectal Cancer Metastases Requires YAP-Controlled Plasticity at the Micrometastatic Stage
Hugo J.G. Snippert et al.
Cancer Res May 2022

Clinical Cancer Research

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
Noboru Yamamoto et al.
Clin Cancer Res May 2022

IL15 and Anti–PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors
Thomas A. Waldmann et al.
Clin Cancer Res May 2022

Molecular Cancer Research

Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications
Yuzhuo Wang et al.
Mol Cancer Res May 2022

Molecular Cancer Therapeutics

Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies
Dennis J. Slamon et al.
Mol Cancer Ther May 2022

Cancer Research Communications

Race-associated Molecular Changes in Gynecologic Malignancies
Anil K. Sood et al.
Cancer Res Commun May 2022

Blood Cancer Discovery

Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies
Stefanie R. Bailey et al.
Blood Cancer Discovery April 2022

Cancer Discovery

Cancer-Causative Mutations Occurring in Early Embryogenesis
Fresia Pareja et al.
Cancer Discov April 2022

Cancer Epidemiology, Biomarkers & Prevention

Estimation of the Exposure–Response Relation between Benzene and Acute Myeloid Leukemia by Combining Epidemiologic, Human Biomarker, and Animal Data
Bernice Scholten et al.
Cancer Epidemiol Bio Prev April 2022

Cancer Immunology Research

Molecular Signature of Tumor-Associated High Endothelial Venules That Can Predict Breast Cancer Survival
Junko Sawada et al.
Cancer Immunol Res April 2022

Cancer Prevention Research

Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study
Sohee Kwon et al.
Cancer Prev Res April 2022

Cancer Research

Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy
Mario R. Fernandez et al.
Cancer Res April 2022

Ketogenesis Attenuates KLF5-Dependent Production of CXCL12 to Overcome the Immunosuppressive Tumor Microenvironment in Colorectal Cancer
Ruozheng Wei et al.
Cancer Res April 2022

Clinical Cancer Research

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Cynthia X. Ma et al.
Clin Cancer Res April 2022

Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Sara M. Tolaney et al.
Clin Cancer Res April 2022

Molecular Cancer Research

MIRO2 Regulates Prostate Cancer Cell Growth via GCN1-Dependent Stress Signaling
Madison Furnish et al.
Mol Cancer Res April 2022

Molecular Cancer Therapeutics

(+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Ryan N. Cole et al.
Mol Cancer Ther April 2022

Blood Cancer Discovery

Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies
Sisi Zheng et al.
Blood Cancer Discovery March 2022

Cancer Discovery

Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
Meng-Ju Wu et al.
Cancer Discov March 2022

Cancer Epidemiology, Biomarkers & Prevention

Racial/Ethnic Differences in Cancer Diagnosed after Metastasis: Absolute Burden and Deaths Potentially Avoidable through Earlier Detection
Christina A. Clarke et al.
Cancer Epidemiol Bio Prev March 2022

Cancer Immunology Research

Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia
Natalia Colomar-Carando et al.
Cancer Immunol Res March 2022

Cancer Prevention Research

Preparation of a Beverage Containing Freeze-Dried Watercress for a Clinical Trial of Carcinogen and Toxicant Detoxification
Melissa J.L. Bonorden et al.
Cancer Prev Res March 2022

Cancer Research

Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma
Meghan C. Ferrall-Fairbanks et al.
Cancer Res March 2022

Combined Inactivation of CTPS1 and ATR Is Synthetically Lethal to MYC-Overexpressing Cancer Cells
Zhe Sun et al.
Cancer Res March 2022

Clinical Cancer Research

Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection
Ramya Ramaswami et al.
Clin Cancer Res March 2022

Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Albiruni R. Abdul Razak et al.
Clin Cancer Res March 2022

Molecular Cancer Research

Disruption of β-Catenin–Dependent Wnt Signaling in Colon Cancer Cells Remodels the Microenvironment to Promote Tumor Invasion
George T. Chen et al.
Mol Cancer Res March 2022

Molecular Cancer Therapeutics

Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
Jennifer R. Diamond et al.
Mol Cancer Ther March 2022

Blood Cancer Discovery

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
Michael A. Pulsipher et al.
Blood Cancer Discovery February 2022

Cancer Discovery

Live-Cell Imaging Shows Uneven Segregation of Extrachromosomal DNA Elements and Transcriptionally Active Extrachromosomal DNA Hubs in Cancer
Eunhee Yi et al.
Cancer Discov February 2022

Cancer Epidemiology, Biomarkers & Prevention

Comparison of Fecal Sample Collection Methods for Microbial Analysis Embedded within Colorectal Cancer Screening Programs
Semi Zouiouich et al.
Cancer Epidemiol Bio Prev February 2022

Cancer Immunology Research

NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
Ti Wen et al.
Cancer Immunol Res February 2022

Cancer Prevention Research

Progestin Significantly Inhibits Carcinogenesis in the Mogp-TAg Transgenic Mouse Model of Fallopian Tube Cancer
Omar L. Nelson et al.
Cancer Prev Res February 2022

Cancer Research

Targeting Chemotherapy to Decondensed H3K27me3-Marked Chromatin of AML Cells Enhances Leukemia Suppression
Patrizia Porazzi et al.
Cancer Res February 2022

An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression
Manuel C. Scheidmann et al.
Cancer Res February 2022

Clinical Cancer Research

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
Andrew B. Lassman et al.
Clin Cancer Res February 2022

First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
Jian Zhang et al.
Clin Cancer Res February 2022

Molecular Cancer Research

Glioblastoma–Astrocyte Connexin 43 Gap Junctions Promote Tumor Invasion
Sean McCutcheon et al.
Mol Cancer Res February 2022

Molecular Cancer Therapeutics

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
Nicole Gormley et al.
Mol Cancer Ther February 2022

Blood Cancer Discovery

NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity
Rebecca M. Richards et al.
Blood Cancer Discovery January 2022

Cancer Discovery

Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
Claudio Vernieri et al.
Cancer Discov January 2022

Cancer Epidemiology, Biomarkers & Prevention

Work-Related Stress Was Not Associated with Increased Cancer Risk in a Population-Based Cohort Setting
Jenny Hadrévi et al.
Cancer Epidemiol Bio Prev January 2022

Cancer Immunology Research

Imaging α-GalCer–Activated iNKT Cells in a Hepatic Metastatic Environment
Liane Babes et al.
Cancer Immunol Res January 2022

Cancer Prevention Research

Single-cell RNA Sequencing Reveals How the Aryl Hydrocarbon Receptor Shapes Cellular Differentiation Potency in the Mouse Colon
Yongjian Yang et al.
Cancer Prev Res January 2022

Cancer Research

EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody–Drug Conjugate HER3–DXd
Heidi M. Haikala et al.
Cancer Res January 2022

T Cells Promote Metastasis by Regulating Extracellular Matrix Remodeling following Chemotherapy
Jozafina Haj-Shomaly et al.
Cancer Res January 2022

Clinical Cancer Research

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
Kathleen N. Moore et al.
Clin Cancer Res January 2022

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Geraldine O'Sullivan Coyne et al.
Clin Cancer Res January 2022

Molecular Cancer Research

A Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma by Suppressing LSD1
Aditya Wirawan et al.
Mol Cancer Res January 2022

Molecular Cancer Therapeutics

SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
Kristen Jensen-Pergakes et al.
Mol Cancer Ther January 2022